Literature DB >> 11577449

Combined resection of distal aortic arch for T4N0 non-small-cell lung cancer with aortic arch invasion.

M Chida1, M Handa, G Yaginuma, H Suda, S Maeda, H Kazuma.   

Abstract

Three men age: 39-51 years (mean: 43.3 years) with T4N0 lung cancer infiltrating the distal aortic arch underwent combined resection of the left upper lobe, distal aortic arch, and left subclavian artery using partial extracorponeal circulation. Selective cerebral perfusion was used in 2. One underwent induction therapy (CDDP + VP - 16 x 2 + radiation 30 Gy), and all underwent adjuvant therapy. No postoperative complications or postoperative death occurred. Average ICU stay was 2.3 days. All patients are alive without local recurrence. Two were disease-free 37 and 26 months after surgery, and 1 had adrenal gland metastasis 8 months after surgery. Extended resection of the aortic arch in lung cancer is thus feasible and worthwhile in patients with T4N0 non-small-cell lung cancer.

Entities:  

Mesh:

Year:  2001        PMID: 11577449     DOI: 10.1007/bf02913535

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  7 in total

1.  [Combined resection of the descending aorta for lung cancer with aortic invasion].

Authors:  K Kodama; D Doi; M Higashiyama; H Yokouchi; T Kabuto; T Kobayashi; T Hiraishi
Journal:  Kyobu Geka       Date:  1995-05

2.  Extended resection of the left atrium, great vessels, or both for lung cancer.

Authors:  R Tsuchiya; H Asamura; H Kondo; T Goya; T Naruke
Journal:  Ann Thorac Surg       Date:  1994-04       Impact factor: 4.330

3.  Extended operations after induction therapy for stage IIIb (T4) non-small cell lung cancer.

Authors:  P Macchiarini; A R Chapelier; I Monnet; J M Vannetzel; J L Rebischung; J Cerrina; F Parquin; F L Ladurie; B Lenot; P G Dartevelle
Journal:  Ann Thorac Surg       Date:  1994-04       Impact factor: 4.330

4.  Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients.

Authors:  N Martini; M G Kris; B J Flehinger; R J Gralla; M S Bains; M E Burt; R Heelan; P M McCormack; K M Pisters; J R Rigas
Journal:  Ann Thorac Surg       Date:  1993-06       Impact factor: 4.330

5.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

Authors:  R Rosell; J Gómez-Codina; C Camps; J Maestre; J Padille; A Cantó; J L Mate; S Li; J Roig; A Olazábal
Journal:  N Engl J Med       Date:  1994-01-20       Impact factor: 91.245

6.  Combined thoracic aortic or upper digestive tract resection for lung cancer and malignant mediastinal tumor.

Authors:  K Oyama; T Onuki; M Mae; T Adachi; M Kanzaki; M Murasugi; Y Sone; J Kei; M Yokoyama; S Nitta
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-01

7.  Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.

Authors:  K S Albain; V W Rusch; J J Crowley; T W Rice; A T Turrisi; J K Weick; V A Lonchyna; C A Presant; R J McKenna; D R Gandara
Journal:  J Clin Oncol       Date:  1995-08       Impact factor: 44.544

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.